BioSpace News Archive

BioMidwest

American Lung Association Rallies Support for Lung Cancer Survivors at LUNG FORCE Walks Across the Country

2018 National Breathe Deeper Sponsor AbbVie joins fight against the #1 cancer killer

April 10, 2018
·
4 min read
Biotech Beach

Global Genes® Partners with University of Pennsylvania Orphan Disease Center for 2018 RARE Patient Advocacy Symposium

Philadelphia, Pennsylvania on May 19, 2018 Registration is NOW Open! Learn Strategies, Tools and Best Practices for Effective Patient Engagement in Rare Disease Drug Development

April 10, 2018
·
3 min read
FDA

FDA clears first contact lens with light-adaptive technology

The U.S. Food and Drug Administration today cleared the first contact lens to incorporate an additive that automatically darkens the lens when exposed to bright light

April 10, 2018
·
3 min read
JPT Peptide Technologies Launches The Human Proteome Peptide Catalog

JPT Peptide Technologies (JPT) announces the launch of The Human Proteome Peptide Catalog, the first and most comprehensive online resource for validated reference peptides in mass-spectrometry based proteomics.

April 10, 2018
·
2 min read
Drug Development

Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

Pfizer Inc. today announced that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating INLYTA® (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy recommended stopping the trial at a planned interim analysis due to futility.

April 10, 2018
·
11 min read
Drug Development

ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes

First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.

April 10, 2018
·
6 min read
Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights

Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market

April 10, 2018
·
4 min read